Bayer is signaling it has had enough of litigation, leaving the future of a crop protection tool in limbo.
Executives tell the Wall Street Journal they are nearing the end of the road for glyphosate, the main ingredient in RoundUp. CEO Bill Anderson says they are barely breaking even, and litigation costs often put them in the red.
More than 65,000 cases are pending against Bayer right now, and the company has around $16 billion set aside for settlements.
Anderson stands by glyphosate, saying it has been proven safe to use, even by the FDA. Bayer produces roughly 40 percent of the supply used by U.S. farmers.
Related Stories
Food prices increased in December, but not as much as expected, according to the latest Consumer Price Index from the U.S. Bureau of Labor and Statistics.
Structural efficiency supports cattle prices and resilience — breaking it risks higher costs and greater volatility.
Market reaction was bearish for corn and soybeans, with analysts noting that abundant supplies amid tepid demand could keep price pressure on agricultural commodities.
Logistics capacity remains available, but winter volatility favors flexible delivery and marketing plans. NGFA President Mike Seyfert provides insight into grain transportation trends, trade policy, and priorities for the year ahead.
Rising adoption of GLP-1 drugs may gradually reshape food demand, with potential downstream effects on protein markets and consumer purchasing patterns.
Leadership development and bipartisan engagement remain central to advancing agriculture’s priorities in 2026.
